Dhexa

Dihexa (DHEXA) – Neuroscience Research Compound

Angiotensin IV-Derived Peptidomimetic for HGF/c-Met Signaling, Synaptic Biology & Neuroplasticity Research

Dihexa, also referred to as DHEXA or PNB-0408, is an experimental angiotensin IV-derived peptidomimetic investigated in preclinical neuroscience research.

The compound was developed to explore the biological activity of modified angiotensin IV analogues, particularly their possible relationships with neuronal signaling, synaptic structure and learning-associated processes.

Dihexa has attracted scientific attention because early research proposed that it could influence the hepatocyte growth factor (HGF)/c-Met signaling system, a pathway involved in cellular development, neuronal maturation and synaptic organization.

However, the scientific evidence supporting Dihexa requires particularly careful interpretation.

A major 2014 publication reporting Dihexa-related HGF/c-Met activity, synaptogenesis and procognitive effects was formally retracted in April 2025 following findings of fabricated or falsified research data.

An earlier 2013 publication describing metabolically stabilized angiotensin IV analogues also received a formal Notice of Concern.

Consequently, Dihexa's proposed mechanisms and biological effects cannot be regarded as independently established clinical facts.

There are no established human clinical safety or efficacy data supporting Dihexa as a treatment for memory impairment, Alzheimer's disease, cognitive decline or other neurological conditions.

ICAME Pharmacy Dihexa is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is Dihexa?

Dihexa is a synthetic compound developed from research involving angiotensin IV, a biologically active peptide fragment of the renin–angiotensin system.

Angiotensin IV has been investigated in connection with several biological processes, including neuronal signaling and learning-associated pathways.

Researchers developed structurally modified analogues to explore whether changes in peptide chemistry could influence metabolic stability and biological activity.

Dihexa emerged from this research as a chemically modified, low-molecular-weight compound.

Unlike a conventional peptide consisting of an unmodified chain of amino acids, Dihexa contains terminal chemical modifications and an aminohexanoic acid-derived component.

Its structure is therefore more accurately described as a peptidomimetic or modified peptide-derived compound.

Dihexa has been associated with research into:

• Angiotensin IV analogue pharmacology

• HGF/c-Met signaling hypotheses

• Synaptic biology

• Neuronal development

• Dendritic spine formation

• Neuroplasticity

• Learning-related experimental models

• Peptidomimetic design

• Blood–brain barrier research

• Receptor-associated cellular signaling

These are areas of scientific investigation rather than demonstrated therapeutic applications.

Dihexa Molecular Structure

Dihexa is chemically identified as:

N-Hexanoyl-Tyr-Ile-(6-aminohexanoic amide)

Its structure incorporates a tyrosine–isoleucine peptide segment together with chemical modifications intended to influence its physicochemical properties.

Chemical Characteristics

Compound Name: Dihexa

Alternative Name: DHEXA

Development Code: PNB-0408

Classification: Angiotensin IV-Derived Peptidomimetic

Molecular Formula: C₂₇H₄₄N₄O₅

Approximate Molecular Weight: 504.7 g/mol, for the specified neutral compound

CAS Number: 1401708-83-5

The exact molecular specifications of a supplied product must be confirmed through manufacturer documentation.

Chemical form, purity, identity and analytical characteristics should not be assumed from the product name alone.

Dihexa and Angiotensin IV Research

Angiotensin IV (Ang IV) is a peptide fragment derived from the renin–angiotensin system.

Although the renin–angiotensin system is commonly associated with cardiovascular and fluid-balance regulation, angiotensin-derived peptides have also been investigated in neurological research.

Angiotensin IV and related compounds have been studied in connection with:

Neuronal signaling

Learning-associated pathways

Peptide receptor pharmacology

Cognitive research models

Peptide metabolism

Structure–activity relationships

Dihexa was developed as part of efforts to modify angiotensin IV-related structures and examine their experimental biological properties.

Its pharmacology should not be assumed to be identical to that of native angiotensin IV.

Proposed Mechanism: HGF/c-Met Signaling

The hepatocyte growth factor (HGF)/c-Met pathway is involved in multiple biological processes.

HGF is a signaling protein that interacts with the MET receptor tyrosine kinase, commonly called c-Met.

Activation of this system can influence cellular growth, survival, migration, differentiation and tissue organization.

In the nervous system, HGF/c-Met signaling has been investigated in relation to neuronal maturation and synaptic development.

Early Dihexa research proposed that the compound could modulate HGF-associated signaling and thereby influence c-Met-dependent biological processes.

Historical Mechanistic Hypothesis

Dihexa

↓

Proposed Interaction with HGF

↓

Potential Modulation of HGF/c-Met Signaling

↓

Hypothesized Changes in Neuronal Signaling

↓

Experimental Investigation of Synaptic Biology

Important evidence limitation: This pathway diagram represents a historical research hypothesis, not a validated mechanism of Dihexa in humans.

The principal 2014 study supporting this proposed mechanism was retracted in 2025 because of research-integrity findings.

The specific molecular interactions and biological consequences of Dihexa therefore require independent verification.

What Is the HGF/c-Met Pathway?

Hepatocyte growth factor is a multifunctional signaling protein.

Its receptor, c-Met, belongs to the receptor tyrosine kinase family.

The HGF/c-Met system participates in several biological processes, including:

• Cell survival

• Cellular differentiation

• Cell migration

• Tissue development

• Neuronal maturation

• Dendritic growth

• Synaptic development

In neuronal research, HGF/c-Met signaling has been associated with intracellular pathways involving:

PI3K/Akt

MAPK/ERK

Receptor tyrosine kinase signaling

Cellular growth and differentiation

These are established areas of HGF/c-Met biology.

However, the involvement of these pathways in normal neuronal development does not prove that Dihexa safely or effectively modulates them.

Dihexa and Synaptogenesis Research

Synaptogenesis is the biological process through which neurons form new synaptic connections.

Synapses allow neurons to exchange information through chemical or electrical signaling.

Synapse formation is important during nervous system development and contributes to the organization of neural circuits.

Dihexa attracted attention because early preclinical reports proposed effects on synapse-related biological processes.

These included:

Dendritic spine formation

Synaptic connectivity

Neuronal structural adaptation

Hippocampal neuronal signaling

Learning-associated neural pathways

However, the retraction of a central mechanistic study substantially weakens confidence in the reported Dihexa-specific effects.

Synaptogenesis should therefore be presented as an experimental research topic associated with Dihexa, not a proven biological benefit.

Dihexa and Dendritic Spine Research

Dendritic spines are small protrusions found on the dendrites of many neurons.

They are important structural components of excitatory synapses.

Changes in dendritic spine structure and density can accompany neuronal development, learning and changes in neural activity.

Dihexa-related research has historically focused on whether modified angiotensin IV analogues influence dendritic spine biology.

Relevant research topics include:

• Dendritic morphology

• Spine density

• Synaptic structure

• Neuronal maturation

• Synaptic protein organization

• Cellular signaling

Any Dihexa-specific claims concerning increased dendritic spine formation require reliable, independently replicated evidence.

Dihexa and Neuroplasticity

Neuroplasticity refers to the ability of the nervous system to change its structure and function.

It involves numerous processes, including:

Synaptic strengthening

Synaptic weakening

Neuronal connectivity

Dendritic remodeling

Activity-dependent signaling

Functional neural adaptation

Dihexa has been discussed in neuroplasticity research because of its proposed relationship with pathways involved in synaptic organization.

However, there is insufficient reliable evidence to conclude that Dihexa enhances neuroplasticity in humans.

Changes observed in experimental cell systems or animal models cannot be assumed to produce beneficial neurological outcomes.

Dihexa and Learning-Related Research

Learning involves coordinated activity across multiple neural networks.

The hippocampus is particularly important for several forms of learning and memory.

Researchers investigating angiotensin IV-derived compounds have examined experimental models involving spatial learning and memory-associated behavior.

Dihexa was originally developed partly in response to interest in these pathways.

Historical research reported changes in learning-related outcomes in animal models.

However, the evidence base is limited and affected by research-integrity concerns.

The findings do not establish that Dihexa improves learning, memory or cognitive performance in humans.

Dihexa and Hippocampal Biology

The hippocampus is a brain structure involved in memory formation, spatial processing and neural plasticity.

Hippocampal research frequently examines:

Synaptic transmission

Dendritic spine morphology

Neuronal signaling

Learning-associated cellular processes

Neurotrophic pathways

Neural circuit adaptation

Dihexa has been investigated in experimental research involving hippocampal neurons.

Its proposed relationship with synaptic structure remains an area requiring stronger scientific confirmation.

Dihexa and Alzheimer's Disease Research

Alzheimer's disease is a progressive neurodegenerative disorder involving changes in memory, cognition and daily functioning.

Its biology includes multiple interacting processes, such as:

• Amyloid-associated pathology

• Tau-related abnormalities

• Synaptic dysfunction

• Neuroinflammation

• Neuronal loss

• Altered cellular signaling

Researchers have investigated HGF/c-Met biology as one potential area of interest in neurological disease research.

Dihexa was historically discussed as a possible experimental approach to synaptic dysfunction.

However, Dihexa has not been demonstrated to prevent, treat, reverse or cure Alzheimer's disease in humans.

The withdrawal of key supporting publications further limits the conclusions that can be drawn from its early research history.

Dihexa and Blood–Brain Barrier Research

The blood–brain barrier (BBB) regulates the movement of many substances from the circulation into the central nervous system.

Its selective properties are important in neurological drug development.

Dihexa was designed with chemical modifications intended to improve properties relevant to systemic exposure and potential central nervous system activity.

Early preclinical publications described the compound as capable of crossing the blood–brain barrier.

However, the available evidence does not establish human brain exposure, human pharmacokinetics or clinical effectiveness.

Blood–brain barrier penetration in an experimental model is not sufficient to demonstrate therapeutic usefulness or safety.

Dihexa and Peptidomimetic Design

Peptidomimetics are compounds designed to reproduce selected structural or biological features of peptides.

They may contain chemical modifications that alter stability, solubility, receptor interactions or metabolic behavior.

Dihexa is relevant to research involving:

Peptide modification

Terminal chemical protection

Molecular stability

Structure–activity relationships

Angiotensin-derived compound design

Experimental pharmacokinetics

These areas remain scientifically relevant regardless of whether Dihexa's original neurological efficacy hypotheses are ultimately confirmed.

Dihexa and Receptor Tyrosine Kinase Research

Receptor tyrosine kinases are membrane-associated proteins involved in cellular signaling.

The MET receptor is one example.

Receptor activation can initiate intracellular signaling networks that influence cell survival, differentiation and growth.

The HGF/c-Met pathway has been investigated in both neurological biology and cancer research.

Dihexa's proposed relationship with this system raises scientific questions about receptor modulation, signaling specificity and long-term biological consequences.

The exact nature of Dihexa's interaction with this pathway remains insufficiently established.

Important Safety Concern: HGF/c-Met and Cancer Biology

The HGF/c-Met pathway is involved in normal tissue development and repair.

However, abnormal MET signaling is also associated with several cancers.

Dysregulated HGF/c-Met activity can contribute to processes involving cellular proliferation, migration and invasive behavior.

Because Dihexa was historically proposed to enhance HGF-associated signaling, researchers have raised concerns about potential consequences of prolonged pathway modulation.

There is no adequate human safety evidence establishing whether Dihexa increases, decreases or has no effect on cancer risk.

It would therefore be scientifically inappropriate to describe Dihexa as a safe neuroregenerative or cognitive-enhancement compound.

The possible relationship between its proposed mechanism and oncogenic signaling represents an important unresolved safety question.

Scientific Retractions and Evidence Quality

The integrity of published evidence is particularly important when evaluating investigational compounds.

Dihexa's scientific history includes several significant developments.

2013 – Early Peptidomimetic Research

A publication in the Journal of Pharmacology and Experimental Therapeutics evaluated metabolically stabilized angiotensin IV analogues.

The study contributed to early scientific interest in Dihexa.

In September 2021, the journal issued a formal Notice of Concern regarding possible image manipulation.

2014 – Proposed HGF/c-Met Mechanism

A subsequent publication reported that angiotensin IV-derived compounds, including Dihexa, influenced HGF/c-Met-associated signaling and synaptic biology.

April 2025 – Formal Retraction

The 2014 publication was formally retracted following an institutional investigation that identified falsified or fabricated research data.

Related publications concerning angiotensin IV-derived HGF/Met modifiers were also retracted.

Implications for Dihexa Research

These developments substantially reduce confidence in the historical mechanistic evidence.

A retracted study should not be treated as valid proof of Dihexa's efficacy or molecular mechanism.

Independent replication and new, rigorously controlled research are necessary before firm conclusions can be drawn.

Dihexa and Human Clinical Evidence

Dihexa remains an experimental research compound.

No established published human clinical trials demonstrate its safety or efficacy for cognitive enhancement or neurological disease treatment.

There are no validated human therapeutic indications.

There is also insufficient evidence to establish:

Safe human exposure

Effective clinical dosing

Long-term neurological safety

Cancer-related safety

Human pharmacokinetic behavior

Clinically meaningful cognitive benefits

Prevention or treatment of Alzheimer's disease

Consequently, Dihexa should not be promoted as a clinically validated nootropic, memory enhancer or neuroprotective treatment.

Dihexa vs. Conventional Research Peptides

Dihexa's chemical identity and evidence limitations should be considered when comparing it with other compounds in a research peptide catalog.

Potential Research Applications

Dihexa may be relevant to appropriately controlled investigations involving:

• Angiotensin IV analogue chemistry

• Peptidomimetic design

• HGF/c-Met signaling hypotheses

• Receptor tyrosine kinase biology

• Neuronal signaling

• Synaptic biology

• Dendritic spine research

• Neuroplasticity

• Hippocampal biology

• Neuronal development

• Structure–activity relationships

• Experimental neuropharmacology

• Peptide stability

• Blood–brain barrier research

• Neuroscience research methodology

• Reproducibility of historical pharmacological findings

These represent possible scientific research topics, not established therapeutic benefits.

Dihexa Research Overview

Compound Name: Dihexa

Alternative Name: DHEXA

Development Code: PNB-0408

Compound Classification: Angiotensin IV-Derived Peptidomimetic

Molecular Formula: C₂₇H₄₄N₄O₅

Approximate Molecular Weight: 504.7 g/mol

CAS Number: 1401708-83-5

Historical Mechanistic Hypothesis: HGF/c-Met Modulation

Research Fields: Neuroscience / Peptidomimetic Chemistry / Synaptic Biology

Clinical Evidence: No established human efficacy or safety

Important Evidence Limitation: Key mechanistic research retracted in 2025

Product Information

Product Name: Dihexa (DHEXA)

Brand: ICAME Pharmacy

Product Category: Neuroscience Research Compound

Research Classification: Angiotensin IV-Derived Peptidomimetic

Research Areas: Neuronal Signaling / Synaptic Biology / Peptidomimetic Research

Intended Use: Laboratory Research & Development Only

The exact chemical identity and specifications of the supplied material must be verified through manufacturer documentation.

Relevant batch-specific information includes:

• Verified molecular identity

• Chemical form

• Molecular formula and molecular weight

• Analytical purity

• Identity testing

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claim of pharmaceutical quality, human suitability or therapeutic efficacy should be made without appropriate evidence and regulatory authorization.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, cognitive-enhancement, neuroregenerative, anti-aging or other clinical purposes. Not for direct administration to humans or animals.

Dihexa is an experimental compound with an incompletely characterized safety profile.

Key publications concerning its proposed mechanism have been retracted, and reliable human clinical safety and efficacy data are lacking.

Its historical association with HGF/c-Met signaling raises additional unresolved safety questions relevant to cellular growth and cancer biology.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized products for professional laboratory and scientific research applications.

Our portfolio includes research compounds relevant to peptide science, neuroscience, molecular biology, receptor signaling, experimental pharmacology and life sciences research.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.